FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 330 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate... January 11, 2022 Bullies Make Fun Of Little Girl Over Cancer Scars, Her Mom... May 29, 2019 Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line... December 22, 2021 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 Load more HOT NEWS FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation...
